Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Susan Moreton"'
Autor:
Ali Bazargan, Julian Lindsay, Robert Twigger, Ashleigh P Scott, Judith Trotman, Carrie van der Weyden, Lindsay Dunlop, Hang Quach, Luke Coyle, Minh Hua, Lorenz Admojo, Glen A Kennedy, Susan Moreton, Naadir Gutta, Ian Irving, Michael Dickinson, David Kipp, Shyam Panicker, Andrew McQuillan, Sam Yuen, Mansi Bhurani, Pratyush Giri, Christopher McCormack, Allan Zimet, Henry Miles Prince, Dejan Radeski, Eliza A Hawkes, Liane Khoo, James Yeung
Publikováno v:
Leukemialymphoma. 62(2)
We present a retrospective multicenter study of pralatrexate treatment outcomes in an Australian practice setting for patients with relapsed/refractory T-cell lymphoma who had failed 1+ systemic therapies, treated via a compassionate access program.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ef602a20c822d816930773399e713a1
https://pubmed.ncbi.nlm.nih.gov/33026266
https://pubmed.ncbi.nlm.nih.gov/33026266
Autor:
Susan Moreton, Susan Branford, Christopher Arthur, Timothy P. Hughes, Kevin Lynch, Alvin Milner, Rachel Koelmeyer, Kerry Taylor, Anthony P. Schwarer, Robin Filshie
Publikováno v:
Cancer. 110(4)
BACKGROUND. Interferon-alpha (IFN-α) confers a survival advantage for the minority of patients with chronic myeloid leukemia (CML) who achieve a complete cytogenetic response. The question of whether IFN-α-responsive patients can experience further
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c0e3eec2da9faa68920864f9f2941e8e
https://pubmed.ncbi.nlm.nih.gov/17607681
https://pubmed.ncbi.nlm.nih.gov/17607681
Autor:
Robyn Rodwell, Susan Branford, Robin Filshie, Rachel Koelmayer, Nancy Guzzo-Pernell, Deb Taylor, Susan Moreton, K. M. Taylor, Christopher Arthur, Jenny Larson, Kevin Lynch, Alvin Milner, Timothy P. Hughes, Anthony P. Schwarer, Steven Stylian
Publikováno v:
Blood. 108:2142-2142
IFN confers a survival advantage for the minority of patients with CML who achieve a complete cytogenetic response. The 10-year survival rate was reported as 72%. In the IRIS trial only 3% of patients remained on IFN after randomization and 65% cross
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d0664426067b876f1339816ddec2c697
https://doi.org/10.1182/blood.v108.11.2142.2142
https://doi.org/10.1182/blood.v108.11.2142.2142
Autor:
Birky, Susan Moreton1
Publikováno v:
Birder's World. Feb2006, Vol. 20 Issue 1, p25-25. 1p. 5 Color Photographs.